What is the value of the Global Cardiac Biomarkers Market in 2022?

The Global Cardiac Biomarkers Market was valued at US$ 11.8 Billion in 2022.

What are cardiac biomarkers?

Cardiac biomarkers are specific endogenous substances such as hormones, proteins, and enzymes that are released into the bloodstream when cardiovascular conditions occur, indicating abnormalities in cardiac functioning.

What is driving the growth of the Cardiac Biomarkers Market?

The increasing prevalence of cardiovascular diseases, caused by factors such as smoking, obesity, lifestyle changes, and diabetes, is driving the growth of the Cardiac Biomarkers Market. Changing lifestyles have made individuals more susceptible to cardiovascular diseases, increasing the demand for cardiac biomarkers.

Which type of cardiac biomarker leads the market segment?

Troponin leads the type segment of the global Cardiac Biomarkers Market, accounting for a major revenue share of 29.6%.

What are the types of cardiac biomarkers available in the market?

The cardiac biomarkers available in the market include Myoglobin, Troponin, BNP and NT-proBNP, CK-MB, and other types.

Which region leads the global cardiac biomarkers market?

The North America region leads the global cardiac biomarkers market, holding a major share.

Which companies are considered key players in the global cardiac biomarkers market?

Some key players in the global cardiac biomarkers market include Abbott, Siemens Healthineers, F. Hoffmann-La Roche Ltd., Biomérieux SA, Danaher Corporation, Creative Diagnostics, Becton Dickinson and Company, Life Diagnostics, Thermo Fisher Scientific Inc., Novartis AG, and other key players.

What is the role of research and development in the cardiac biomarkers market?

Research and development play a crucial role in the cardiac biomarkers market by advancing techniques and tests for accurate diagnosis and monitoring of cardiac events.

Cardiac Biomarkers Market Size, Share

Global Cardiac Biomarkers Market By Type (Myoglobin, Troponin, BNP and NT-proBNP, CK-MB, and Other Types) By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Other Indications), By Location of Testing, By Region and Companies – Industry Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

- Get a FREE Sample -

Our Clients